FOLD AMICUS THERAPEUTICS, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Global biotechnology company focused on developing transformative rare disease medicines including Fabry and Pompe disease therapies
• • New emphasis: Licensed exclusive U.S. commercialization rights to Phase 3 FSGS drug candidate DMX-200 in April 2025
• • Strategic shift: Definitive merger agreement with BioMarin announced December 2025, $14.50/share cash, expected Q2 2026 close, going private
• • Quantitative highlight: 2025 revenue increased to $521.7M for Galafold (+$63.6M YoY) and $112.5M for Pombiliti+Opfolda (+$42.3M YoY)
• • Noteworthy fact: Patent litigation resolved with generic challengers Teva, Aurobindo, Lupin, with licensing agreements allowing generics from January 30, 2037

Risk Factors

• • Regulatory risk: Pending merger requires Hart-Scott-Rodino Act antitrust approval and clearance from EU and Japanese authorities, risking delays or termination
• • Geopolitical risk: Transaction contingent on foreign direct investment approvals in European and Japanese markets, exposing reliance on international regulatory outcomes
• • Operational risk: Business restricted under merger agreement, limiting indebtedness, asset transactions, share issuance, potentially stifling strategic opportunities
• • Competitive risk: Market erosion threat from competitors’ oral, enzyme replacement, and gene therapies against Galafold® and Pombiliti® + Opfolda®
• • Financial risk: $175 million termination fee payable to BioMarin if merger agreement is terminated under specified circumstances, affecting liquidity and operations

Management Discussion & Analysis

• • Revenue $634.2M, up $105.9M YoY from $528.3M driven by Galafold and Pombiliti+Opfolda growth plus $13.5M currency impact
• • Gross profit $561.3M vs $475.4M; cost of goods sold $72.9M vs $52.9M; operating loss narrowed with net loss $27.1M vs $56.1M
• • Best segment: Pombiliti+Opfolda third-party R&D expenses $48.6M up $3.3M; worst: SG&A expenses $383.5M up $60.1M due to litigation and merger costs
• • Operating cash flow positive $33.1M vs negative $33.9M; investing cash used $46.4M mostly in marketable securities and capex $3.3M; no share issuances under ATM in 2025
• • Management highlights Merger Agreement with BioMarin, expects ongoing R&D expenses, and notes risks from clinical trial outcomes, regulatory environment, and market acceptance

Risk Factors

• • No new or changed risk factors disclosed since 2024 10-K
• • Carried-forward regulatory risk: reliance on FDA approvals for product pipeline advancement
• • Operational risk: dependence on third-party manufacturing affecting supply chain continuity
• • Market risk: competition from alternative therapies potentially impacting market share
• • Financial risk: limited liquidity with cash runway through mid-2025 requiring additional funding

What are the latest FOLD SEC filings in 2026?

AMICUS THERAPEUTICS, INC. (FOLD) has filed a 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did FOLD file its most recent 10-K annual report?

AMICUS THERAPEUTICS, INC. (FOLD) filed its most recent 10-K annual report on February 20, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view FOLD 10-Q quarterly reports?

AMICUS THERAPEUTICS, INC. (FOLD)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every FOLD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has FOLD filed recently?

AMICUS THERAPEUTICS, INC. (FOLD)'s most recent 8-K was filed on April 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find FOLD insider trading activity (Form 4)?

SignalX aggregates every FOLD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does FOLD file with the SEC?

AMICUS THERAPEUTICS, INC. (FOLD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new FOLD filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for AMICUS THERAPEUTICS, INC. (FOLD).

What is FOLD's SEC CIK number?

AMICUS THERAPEUTICS, INC. (FOLD)'s SEC CIK (Central Index Key) number is 1178879. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1178879 to look up all FOLD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find FOLD return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from AMICUS THERAPEUTICS, INC. (FOLD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.